Antithrombotic Management After Intracranial Hemorrhage

Christian E. Cajavilca; Destiny Hooper; Rajeel Imran; Rajan R. Gadhia

doi:10.1007/s11936-019-0771-y

Antithrombotic Management After Intracranial Hemorrhage

Christian E. Cajavilca, Destiny Hooper, Rajeel Imran, Rajan R. Gadhia

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Purpose of review: Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. Recent findings: The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. Summary: We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.

Original language	English (US)
Article number	88
Journal	Current Treatment Options in Cardiovascular Medicine
Volume	21
Issue number	12
DOIs	https://doi.org/10.1007/s11936-019-0771-y
State	Published - Dec 1 2019

Keywords

Antithrombotic
Intracranial hemorrhage
Ischemic stroke

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11936-019-0771-y

Cite this

@article{230aa321a4a44364b527086037cf08a6,

title = "Antithrombotic Management After Intracranial Hemorrhage",

abstract = "Purpose of review: Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. Recent findings: The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. Summary: We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.",

keywords = "Antithrombotic, Intracranial hemorrhage, Ischemic stroke",

author = "Cajavilca, {Christian E.} and Destiny Hooper and Rajeel Imran and Gadhia, {Rajan R.}",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s11936-019-0771-y",

language = "English (US)",

volume = "21",

journal = "Current Treatment Options in Cardiovascular Medicine",

issn = "1092-8464",

publisher = "Springer",

number = "12",

}

TY - JOUR

T1 - Antithrombotic Management After Intracranial Hemorrhage

AU - Cajavilca, Christian E.

AU - Hooper, Destiny

AU - Imran, Rajeel

AU - Gadhia, Rajan R.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Purpose of review: Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. Recent findings: The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. Summary: We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.

AB - Purpose of review: Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. Recent findings: The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. Summary: We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.

KW - Antithrombotic

KW - Intracranial hemorrhage

KW - Ischemic stroke

UR - http://www.scopus.com/inward/record.url?scp=85076358577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076358577&partnerID=8YFLogxK

U2 - 10.1007/s11936-019-0771-y

DO - 10.1007/s11936-019-0771-y

M3 - Review article

AN - SCOPUS:85076358577

SN - 1092-8464

VL - 21

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

IS - 12

M1 - 88

ER -

Antithrombotic Management After Intracranial Hemorrhage

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this